Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial

BACKGROUND: Preclinical evidence suggests that zoledronic acid (ZOL) works synergistically with chemotherapy by enhancing anti-tumor activity. ZOL blocks the mevalonate pathway and may indirectly interact with human epidermal growth factor receptor 2 (HER2) pathway activation. The clinical efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Crocamo, Susanne, Binato, Renata, de Paula, Bruno, Vignal, Giselle, Magalhães, Lídia, Sarmento, Roberta, Accioly, Maria Theresa, Small, Isabele, Gioia, Sandra, Maroun, Pedro, Moutinho, Pamela, Freitas, Vivianne, Catein, Karuline, Abdelhay, Eliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545654/
https://www.ncbi.nlm.nih.gov/pubmed/31210800
http://dx.doi.org/10.1177/1758835919853971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545654/
https://www.ncbi.nlm.nih.gov/pubmed/31210800
http://dx.doi.org/10.1177/1758835919853971

Ejemplares similares